Oral LW402 for moderate-to-severe atopic dermatitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind, multicenter trial compares oral LW402 to placebo in adults with moderate-to-severe atopic dermatitis who have had the condition for at least one year. Participants are 18 to 75 years old and must meet established skin severity criteria. The study includes regular safety monitoring and aims to evaluate both efficacy and safety of LW402 over a defined treatment period. A sponsor-open design means the sponsor may be aware of treatment assignment, while investigators remain blinded to reduce bias. The trial is conducted at multiple clinical sites, with primary endpoints likely focusing on changes in skin symptoms and overall disease activity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects voluntarily provided informed consent and agreed to participate in the study.
* Gender: no restrictions; Age: 18 to 75 years inclusive (as of the date of signing the informed consent form).
* At screening, subjects met the Hanifin-Rajka diagnostic criteria for atopic dermatitis (AD) (Appendix 4) and had a documented AD history of ≥1 year prior to screening.
* At screening and baseline visits, subjects were required to have moderate-to-severe atopic dermatitis (AD) with all three of the following criteria satisfied:

  * Total AD lesion area ≥ 10% of body surface area (BSA)
  * Investigator's Global Assessment (IGA) score ≥ 3
  * Eczema Area and Severity Index (EASI) score ≥ 16

Exclusion Criteria:

* Subjects with a documented history of hypersensitivity to Janus kinase (JAK) inhibitors.
* Subjects with current or a history of autoimmune diseases other than atopic dermatitis (AD) (e.g., systemic lupus erythematosus \[SLE\], inflammatory bowel disease \[IBD\], Felty's syndrome, scleroderma, inflammatory myopathy, other connective tissue diseases, overlap syndrome) or other skin conditions that may interfere with AD assessment (e.g., contact dermatitis, psoriasis).

Where it's running

• Peking University People's Hospital
  Beijing, China Recruiting

Study contacts

• Principal investigator: Janzhong Zhang — Peking University People's Hospital
• Study coordinator: Barbara Chen
• Email: barbara@lwbiopharma.com
• Phone: +86-21-63634910

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• A Phase 3 test of Rezpegaldesleukin (NKTR-358) for moderate-to-severe atopic dermatitis in patients 12 years and older

  This Phase 3 study tests whether Rezpegaldesleukin helps people aged 12 and up with moderate-to-severe atopic dermatitis compared to placebo.

  Recruiting at 13 sites Phase 3 Nektar Therapeutics · Birmingham, Alabama and 12 other locations · NCT07711418

• Rezpegaldesleukin for moderate-to-severe atopic dermatitis in people 12 and older

  This study tests whether Rezpegaldesleukin helps people aged 12 and up with moderate-to-severe atopic dermatitis compared with a placebo.

  Recruiting at 20 sites Phase 3 Nektar Therapeutics · Phoenix, Arizona and 19 other locations · NCT07690371

• Nemolizumab for infants with moderate-to-severe atopic dermatitis

  This study tests whether nemolizumab can be safely given to infants aged 6 to under 24 months to help manage moderate-to-severe eczema when topical treatments alone aren’t enough.

  Recruiting Phase 2 Galderma R&D · San Antonio, Texas · NCT07660835

• SYX-5219 in healthy adults and adults with moderate-to-severe atopic dermatitis

  This trial will test oral SYX-5219 in healthy adults and in adults with moderate-to-severe atopic dermatitis to see if it is safe, well tolerated, and how the drug is processed in the body.

  Recruiting at 12 sites Phase 1 Sitryx Therapeutics Ltd · Arkansas City, Arkansas and 13 other locations · NCT07558668

• SHR-1905 treatment for moderate-to-severe atopic dermatitis

  This trial will test whether SHR-1905 injections help adults aged 18–75 who have moderate-to-severe atopic dermatitis.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Guangzhou, Guangdong · NCT07211542

• TRB-061 injections for healthy adults and people with moderate-to-severe atopic dermatitis

  This trial will test subcutaneous TRB-061 injections in healthy adults and adults with moderate-to-severe atopic dermatitis to check safety, dosing, and how the drug acts in the body.

  Recruiting at 18 sites Phase 1 TRex Bio, Inc. · Deakin, Australian Capital Territory and 18 other locations · NCT06934252

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.